Close
Enter your
text here

Clinical Trials

Featured Researcher – Jamie Jackson, PhD
 Featured Researcher – Jamie Jackson, PhD 150 150 Alaina Doklovic
By: Alaina Doklovic

Jamie Jackson, PhD, is a principal investigator in the Center for Biobehavioral Health in the Abigail Wexner Medical Research Institute at Nationwide Children’s Hospital, an assistant professor of Pediatrics and Psychology in the College of Medicine and Department of Psychology at The Ohio State University, and a licensed clinical health psychologist. Dr. Jackson attended graduate…

Improving Medication Adherence and Clinical Outcomes After Hematopoietic Stem Cell Transplant
 Improving Medication Adherence and Clinical Outcomes After Hematopoietic Stem Cell Transplant 1024 683 JoAnna Pendergrass, DVM
By: JoAnna Pendergrass, DVM

A clinical trial is evaluating the acceptability and efficacy of a mobile app in improving medication adherence, symptoms and clinical outcomes in pediatric hematopoietic stem cell patients. A research team led by Micah Skeens, PhD, APRN, FAAN, principal investigator in the Center for Biobehavioral Health at the Abigail Wexner Research Institute, assistant professor of pediatrics…

The True History of the Nuremberg Code: Leo Alexander’s Blueprint Uncovered
 The True History of the Nuremberg Code: Leo Alexander’s Blueprint Uncovered 150 150 Abbie Miller
By: Abbie Miller

An investigation of Duke University’s Medical Center’s Archives boxes labeled “Alexander’s Papers” reveals a document containing six principles, which were included nearly word-for-word in the Nuremberg Code.  At the end of the famous Doctors’ Trial, the trial of Nazi doctors for their crimes and treatment of people who were identified as “research participants,” Judge Sebring…

Improving Racial Diversity and Equity in Clinical Trials
 Improving Racial Diversity and Equity in Clinical Trials 1024 511 Jeb Phillips
By: Jeb Phillips

There is now broad consensus across medicine that clinical trials must be more representative of minority populations. How can that be achieved? Last year, a group of Nationwide Children’s Hospital neonatologists published an unusually pointed critique of racial and ethnic representation in neonatal clinical trials in the Journal of Perinatology. They wrote that the lack…

Therapy With Double-Bright Natural Killer Cell Infusions Increases Response Rates Among Frail Patients With Acute Myeloid Leukemia
 Therapy With Double-Bright Natural Killer Cell Infusions Increases Response Rates Among Frail Patients With Acute Myeloid Leukemia 969 533 Jessica Nye, PhD
By: Jessica Nye, PhD
Illustration of NK Cells, T Cells, other immune cells floating across white background

A case series of 13 patients with relapsed/refractory acute myeloid leukemia (AML) finds that a novel approach using repeated infusions of cultured natural killer (NK) cells increases overall and complete response rates. NK cells are lymphocytes – white blood cell components of the innate immune response – that have anti-leukemic properties. Although efforts to incorporate…

Leaving No Stone Unturned: Nationwide Children’s Joins Children’s Oncology Group Pediatric Early Phase Clinical Trial Network
 Leaving No Stone Unturned: Nationwide Children’s Joins Children’s Oncology Group Pediatric Early Phase Clinical Trial Network 1024 683 Natalie Wilson
By: Natalie Wilson

The Children’s Oncology Group (COG), the world’s largest and most recognized pediatric cancer research collaborative, recently selected Nationwide Children’s Hospital to join its Pediatric Early Phase Clinical Trial Network (PEP-CTN) through a peer review process. The COG PEP-CTN is a re-iteration of the COG Phase 1/Pilot Consortium and is comprised of 21 core member sites…